Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 27

1.

Diagnostic accuracy of whole-body MRI versus standard imaging pathways for metastatic disease in newly diagnosed non-small-cell lung cancer: the prospective Streamline L trial.

Taylor SA, Mallett S, Ball S, Beare S, Bhatnagar G, Bhowmik A, Boavida P, Bridgewater J, Clarke CS, Duggan M, Ellis S, Glynne-Jones R, Goh V, Groves AM, Hameeduddin A, Janes SM, Johnston EW, Koh DM, Lock S, Miles A, Morris S, Morton A, Navani N, Oliver A, O'Shaughnessy T, Padhani AR, Prezzi D, Punwani S, Quinn L, Rafiee H, Reczko K, Rockall AG, Russell P, Sidhu HS, Strickland N, Tarver K, Teague J, Halligan S; Streamline investigators.

Lancet Respir Med. 2019 Jun;7(6):523-532. doi: 10.1016/S2213-2600(19)30090-6. Epub 2019 May 9.

2.

Diagnostic accuracy of whole-body MRI versus standard imaging pathways for metastatic disease in newly diagnosed colorectal cancer: the prospective Streamline C trial.

Taylor SA, Mallett S, Beare S, Bhatnagar G, Blunt D, Boavida P, Bridgewater J, Clarke CS, Duggan M, Ellis S, Glynne-Jones R, Goh V, Groves AM, Hameeduddin A, Janes SM, Johnston EW, Koh DM, Miles A, Morris S, Morton A, Navani N, O'Donohue J, Oliver A, Padhani AR, Pardoe H, Patel U, Punwani S, Quinn L, Rafiee H, Reczko K, Rockall AG, Shahabuddin K, Sidhu HS, Teague J, Thaha MA, Train M, van Ree K, Wijeyekoon S, Halligan S; Streamline investigators.

Lancet Gastroenterol Hepatol. 2019 Jul;4(7):529-537. doi: 10.1016/S2468-1253(19)30056-1. Epub 2019 May 9.

3.

Patient preferences for whole-body MRI or conventional staging pathways in lung and colorectal cancer: a discrete choice experiment.

Miles A, Taylor SA, Evans REC, Halligan S, Beare S, Bridgewater J, Goh V, Janes S, Navani N, Oliver A, Morton A, Rockall A, Clarke CS, Morris S; STREAMLINE investigators.

Eur Radiol. 2019 Jul;29(7):3889-3900. doi: 10.1007/s00330-019-06153-4. Epub 2019 Apr 1.

4.

Rapid Integration of Zika Virus Prevention Within Sexual and Reproductive Health Services and Beyond: Programmatic Lessons From Latin America and the Caribbean.

Beare S, Simpson E, Gray K, Andjelic D.

Glob Health Sci Pract. 2019 Mar 29;7(1):116-127. doi: 10.9745/GHSP-D-18-00356. Print 2019 Mar 22.

5.

BACCHUS: A randomised non-comparative phase II study of neoadjuvant chemotherapy (NACT) in patients with locally advanced rectal cancer (LARC).

Glynne-Jones R, Hall MR, Lopes A, Pearce S, Goh V, Bosompem S, Bridgewater J, Chau I, Wasan H, Moran B, Melcher L, West NP, Quirke P, Wong WL, Beare S, Hava N, Duggan M, Harrison M.

Heliyon. 2018 Sep 22;4(9):e00804. doi: 10.1016/j.heliyon.2018.e00804. eCollection 2018 Sep.

6.

PHOTOSTENT-02: porfimer sodium photodynamic therapy plus stenting versus stenting alone in patients with locally advanced or metastatic biliary tract cancer.

Pereira SP, Jitlal M, Duggan M, Lawrie E, Beare S, O'Donoghue P, Wasan HS, Valle JW, Bridgewater J.

ESMO Open. 2018 Jul 23;3(5):e000379. doi: 10.1136/esmoopen-2018-000379. eCollection 2018.

7.

Circulating biomarkers during treatment in patients with advanced biliary tract cancer receiving cediranib in the UK ABC-03 trial.

Backen AC, Lopes A, Wasan H, Palmer DH, Duggan M, Cunningham D, Anthoney A, Corrie PG, Madhusudan S, Maraveyas A, Ross PJ, Waters JS, Steward WP, Rees C, McNamara MG, Beare S, Bridgewater JA, Dive C, Valle JW.

Br J Cancer. 2018 Jul;119(1):27-35. doi: 10.1038/s41416-018-0132-8. Epub 2018 Jun 21.

8.

Perceived patient burden and acceptability of whole body MRI for staging lung and colorectal cancer; comparison with standard staging investigations.

Evans RE, Taylor SA, Beare S, Halligan S, Morton A, Oliver A, Rockall A, Miles A.

Br J Radiol. 2018 Jun;91(1086):20170731. doi: 10.1259/bjr.20170731. Epub 2018 Mar 20.

9.

Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial.

Seddon B, Strauss SJ, Whelan J, Leahy M, Woll PJ, Cowie F, Rothermundt C, Wood Z, Benson C, Ali N, Marples M, Veal GJ, Jamieson D, Küver K, Tirabosco R, Forsyth S, Nash S, Dehbi HM, Beare S.

Lancet Oncol. 2017 Oct;18(10):1397-1410. doi: 10.1016/S1470-2045(17)30622-8. Epub 2017 Sep 4.

10.

Preoperative chemoradiation with capecitabine, irinotecan and cetuximab in rectal cancer: significance of pre-treatment and post-resection RAS mutations.

Gollins S, West N, Sebag-Montefiore D, Myint AS, Saunders M, Susnerwala S, Quirke P, Essapen S, Samuel L, Sizer B, Worlding J, Southward K, Hemmings G, Tinkler-Hundal E, Taylor M, Bottomley D, Chambers P, Lawrie E, Lopes A, Beare S.

Br J Cancer. 2017 Oct 24;117(9):1286-1294. doi: 10.1038/bjc.2017.294. Epub 2017 Aug 31.

11.

Streamlining staging of lung and colorectal cancer with whole body MRI; study protocols for two multicentre, non-randomised, single-arm, prospective diagnostic accuracy studies (Streamline C and Streamline L).

Taylor SA, Mallett S, Miles A, Beare S, Bhatnagar G, Bridgewater J, Glynne-Jones R, Goh V, Groves AM, Janes SM, Koh DM, Morris S, Morton A, Navani N, Oliver A, Padhani AR, Punwani S, Rockall AG, Halligan S.

BMC Cancer. 2017 May 2;17(1):299. doi: 10.1186/s12885-017-3281-x.

12.

Best time to assess complete clinical response after chemoradiotherapy in squamous cell carcinoma of the anus (ACT II): a post-hoc analysis of randomised controlled phase 3 trial.

Glynne-Jones R, Sebag-Montefiore D, Meadows HM, Cunningham D, Begum R, Adab F, Benstead K, Harte RJ, Stewart J, Beare S, Hackshaw A, Kadalayil L; ACT II study group.

Lancet Oncol. 2017 Mar;18(3):347-356. doi: 10.1016/S1470-2045(17)30071-2. Epub 2017 Feb 11. Erratum in: Lancet Oncol. 2017 Apr;18(4):e196.

13.

Erratum to: A phase 1b study of Selumetinib in combination with Cisplatin and Gemcitabine in advanced or metastatic biliary tract cancer: the ABC-04 study.

Bridgewater J, Lopes A, Beare S, Duggan M, Lee D, Ricamara M, McEntee D, Sukumaran A, Wasan H, Valle JW.

BMC Cancer. 2016 Jun 21;16(1):369. No abstract available.

14.

A phase 1b study of Selumetinib in combination with Cisplatin and Gemcitabine in advanced or metastatic biliary tract cancer: the ABC-04 study.

Bridgewater J, Lopes A, Beare S, Duggan M, Lee D, Ricamara M, McEntee D, Sukumaran A, Wasan H, Valle JW.

BMC Cancer. 2016 Feb 24;16:153. doi: 10.1186/s12885-016-2174-8. Erratum in: BMC Cancer. 2016;16(1):369.

15.

Bevacizumab and Combination Chemotherapy in rectal cancer Until Surgery (BACCHUS): a phase II, multicentre, open-label, randomised study of neoadjuvant chemotherapy alone in patients with high-risk cancer of the rectum.

Glynne-Jones R, Hava N, Goh V, Bosompem S, Bridgewater J, Chau I, Gaya A, Wasan H, Moran B, Melcher L, MacDonald A, Osborne M, Beare S, Jitlal M, Lopes A, Hall M, West N, Quirke P, Wong WL, Harrison M; Bacchus investigators.

BMC Cancer. 2015 Oct 23;15:764. doi: 10.1186/s12885-015-1764-1.

16.

Cediranib or placebo in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer (ABC-03): a randomised phase 2 trial.

Valle JW, Wasan H, Lopes A, Backen AC, Palmer DH, Morris K, Duggan M, Cunningham D, Anthoney DA, Corrie P, Madhusudan S, Maraveyas A, Ross PJ, Waters JS, Steward WP, Rees C, Beare S, Dive C, Bridgewater JA.

Lancet Oncol. 2015 Aug;16(8):967-78. doi: 10.1016/S1470-2045(15)00139-4. Epub 2015 Jul 12. Erratum in: Lancet Oncol. 2015 Sep;16(9):e427.

17.

Tumour- and treatment-related colostomy rates following mitomycin C or cisplatin chemoradiation with or without maintenance chemotherapy in squamous cell carcinoma of the anus in the ACT II trial.

Glynne-Jones R, Kadalayil L, Meadows HM, Cunningham D, Samuel L, Geh JI, Lowdell C, James R, Beare S, Begum R, Ledermann JA, Sebag-Montefiore D; ACT II Study Group.

Ann Oncol. 2014 Aug;25(8):1616-22. doi: 10.1093/annonc/mdu188. Epub 2014 May 14.

PMID:
24827136
18.

Cisplatin and gemcitabine for advanced biliary tract cancer: a meta-analysis of two randomised trials.

Valle JW, Furuse J, Jitlal M, Beare S, Mizuno N, Wasan H, Bridgewater J, Okusaka T.

Ann Oncol. 2014 Feb;25(2):391-8. doi: 10.1093/annonc/mdt540. Epub 2013 Dec 18.

PMID:
24351397
19.

A randomised phase II/III trial of 3-weekly cisplatin-based sequential transarterial chemoembolisation vs embolisation alone for hepatocellular carcinoma.

Meyer T, Kirkwood A, Roughton M, Beare S, Tsochatzis E, Yu D, Davies N, Williams E, Pereira SP, Hochhauser D, Mayer A, Gillmore R, O'Beirne J, Patch D, Burroughs AK.

Br J Cancer. 2013 Apr 2;108(6):1252-9. doi: 10.1038/bjc.2013.85. Epub 2013 Feb 28.

20.

Capturing data on colostomy formation in anal cancer.

Glynne-Jones R, Beare S, Begum R, Kadalayil L.

J Clin Oncol. 2013 Jan 1;31(1):164. doi: 10.1200/JCO.2012.44.2293. Epub 2012 Nov 19. No abstract available.

PMID:
23169498
21.

Ablation with low-dose radioiodine and thyrotropin alfa in thyroid cancer.

Mallick U, Harmer C, Yap B, Wadsley J, Clarke S, Moss L, Nicol A, Clark PM, Farnell K, McCready R, Smellie J, Franklyn JA, John R, Nutting CM, Newbold K, Lemon C, Gerrard G, Abdel-Hamid A, Hardman J, Macias E, Roques T, Whitaker S, Vijayan R, Alvarez P, Beare S, Forsyth S, Kadalayil L, Hackshaw A.

N Engl J Med. 2012 May 3;366(18):1674-85. doi: 10.1056/NEJMoa1109589.

22.

A Phase II Study of Docetaxel in Chemotherapy-Naïve Patients With Recurrent or Metastatic Adult Soft Tissue Sarcoma.

Bramwell V, Blackstein M, Belanger K, Verma S, Beare S, Eisenhauer E.

Sarcoma. 1998;2(1):29-33. doi: 10.1080/13577149878136.

23.

A phase I dose-escalating study of DaunoXome, liposomal daunorubicin, in metastatic breast cancer.

O'Byrne KJ, Thomas AL, Sharma RA, DeCatris M, Shields F, Beare S, Steward WP.

Br J Cancer. 2002 Jul 1;87(1):15-20.

24.

Phase I trial of sequential topotecan followed by etoposide in adults with myeloid leukemia: a National Cancer Institute of Canada Clinical Trials Group Study.

Crump M, Lipton J, Hedley D, Sutton D, Shepherd F, Minden M, Stewart K, Beare S, Eisenhauer E.

Leukemia. 1999 Mar;13(3):343-7.

PMID:
10086724
25.

Randomized phase II study of two schedules of topotecan in previously treated patients with ovarian cancer: a National Cancer Institute of Canada Clinical Trials Group study.

Hoskins P, Eisenhauer E, Beare S, Roy M, Drouin P, Stuart G, Bryson P, Grimshaw R, Capstick V, Zee B.

J Clin Oncol. 1998 Jun;16(6):2233-7.

PMID:
9626225
26.

Plasma free iron and chemotherapy toxicity.

Beare S, Steward WP.

Lancet. 1996 Feb 10;347(8998):342-3. No abstract available.

PMID:
8598694
27.

Children with Down's syndrome: a look at some current ideas on management.

Beare S.

Health Visit. 1979 Jul;52(7):266-8. No abstract available.

PMID:
87390

Supplemental Content

Support Center